This page covers procedure-linked medtech platforms: robotic surgery systems, cardiovascular devices, structural-heart implants, orthopedics, surgical equipment, imaging, point-of-care ultrasound, CNS navigation and delivery, sleep therapy, diabetes sensors, service, and consumables used by hospitals, physicians, home-care channels, biopharma partners, and patients. Aging and chronic disease help the node only when more procedures, higher installed-base use, more implants, imaging utilization, resupply, workflow adoption, and replacements convert into revenue growth, gross margin, free cash flow, and guidance. The current basket read ranks ISRG and EW as the cleanest source-backed economics; BSX, SYK, and MDT are large procedure platforms that need chart or execution confirmation; BFLY and CLPT are clear direct-fit small-cap additions but sit at the back because both still need cash-conversion proof.
What the stack is: procedure and medtech platforms are devices, systems, implants, software, service contracts, and consumables used to diagnose, treat, monitor, or replace diseased anatomy in surgical, cardiovascular, orthopedic, respiratory, diabetes, imaging, point-of-care ultrasound, and CNS procedure workflows.
What it does: the stack turns patient volume into procedures, scans, implants, robotic-case use, ultrasound exams, CNS delivery cases, sensors, masks, disposables, service visits, software workflow, and replacement cycles that can be billed by hospitals, physicians, home-care channels, biopharma partners, and device vendors.
Main pieces: robotic systems, limited-life instruments, implantable valves and orthopedic joints, electrophysiology and vascular catheters, imaging scanners, ultrasound probes, CNS navigation hardware, drug-delivery cannulas, contrast media, sleep and breathing devices, continuous glucose monitoring sensors, service contracts, and field-support teams.
Where it sits: in operating rooms, catheterization and electrophysiology labs, imaging suites, ambulatory surgery centers, hospital supply rooms, physician practices, home-care resupply channels, bedside and point-of-care ultrasound workflows, CNS procedure suites, and patient-worn or bedside monitoring workflows.
How the theme uses it: older patients and chronic-disease populations need more procedures, monitoring, scans, valve interventions, joint replacements, respiratory therapy, and diabetes care; the theme pays companies only when utilization converts into reported revenue, recurring mix, margin, free cash flow, and guidance.
Terms used later: installed base means systems already placed with customers; utilization means procedures or use per installed system; recurring revenue means instruments, accessories, service, consumables, sensors, masks, and resupply tied to repeat use; TAVR means transcatheter aortic valve replacement; TMTT means transcatheter mitral and tricuspid therapies; organic growth excludes currency and acquisition effects.
Report boundary: this node is a tactical report layer. It ranks the current value-chain basket, setup labels, confirmation triggers, invalidation checks, and chart provenance. Durable company, sector, and theme research stays in the linked knowledge pages. Price and volume context comes from read-only discovery daily_ohlc through 2026-06-18. Static price levels are not embedded in the HTML or node JSON; selected-security charts resolve through the local report API.
Current Setup
Procedure conversion gateUtilization must become recurring revenue, margin, and cash.
Procedure demand is useful only when systems, implants, sensors, resupply, imaging, service, and replacements show up in reported sales, mix, operating margin, and free cash flow.
Best current proofISRG and EW have the cleanest direct evidence.
ISRG has Q1 procedure and recurring-revenue strength; EW has TAVR, TMTT, and raised FY2026 guidance.
Conversion gateLarge platforms and new small caps need Q2-H2 execution proof.
BSX, SYK, MDT, RMD, ABT, GEHC, ZBH, BFLY, and CLPT need margin, cash, guidance, or organic-growth follow-through.
Primary constraintHospital budgets and cost leakage can absorb demand.
Reimbursement, tariffs, product quality, integration, litigation, China, and weak charts keep timing selective.
Demand sourceAging + chronic disease
Use pathProcedures, scans, probes
Revenue routeImplants, service, software
Proof pointMargin, FCF, guide
Aging demand raises procedure volume, chronic-device use, hospital imaging utilization, point-of-care diagnostics, CNS delivery needs, and replacement demand, but higher activity is not enough by itself. This node ranks companies where that activity can become recurring revenue, procedure-linked sales, service margin, software mix, cash flow, or guidance. The confirming evidence is procedure growth, utilization per installed system, implant volume, ultrasound adoption, CNS partner procedure use, sensor or mask resupply, backlog conversion, gross margin, operating margin, and free cash flow.
The strongest current evidence sits in names where utilization is already visible. ISRG reported Q1 2026 revenue of $2.7708B, double-digit procedure growth, and recurring revenue at 86%; EW reported Q1 2026 sales of $1.6486B, TAVR growth of 14.4%, TMTT growth of 51.9%, and raised 2026 sales guidance; BSX reported Q1 2026 net sales of $5.203B with Cardiovascular organic growth of 11.2%; SYK maintained 8.0%-9.5% FY2026 organic growth guidance after a first-quarter disruption; MDT's June 3 release showed FY2026 organic growth of 5.8% and Q4 organic growth of 6.6%; RMD reported Q3 FY2026 revenue of $1.431B with 62.2% GAAP gross margin; BFLY reported Q1 2026 revenue growth of 25% with software and other services up to $11.9M; CLPT reported Q1 2026 revenue growth of 43% with more than 175 activated centers and more than 60 biopharma partners. The next useful proof is Q2 and Q3 procedure growth, guidance durability, margin bridge, and cash conversion.
Hospital budgets, reimbursement, tariffs, freight, supplier issues, product quality, integration, litigation, China exposure, PCS weakness, PDx supply, sales-force disruption, debt, dilution, and weak charts can dilute the procedure-demand signal. BSX has PFA, WATCHMAN, Penumbra, and FCF tests; SYK needs proof the Q1 disruption is behind it; MDT still needs FY2027 margin and cash evidence after MiniMed separation; ABT carries Exact Sciences debt and dilution; GEHC needs guide and margin repair; ZBH needs better organic growth and commercial execution; BFLY must prove Q1 licensing and software mix are repeatable; CLPT must turn IRRA integration and partner activity into lower cash burn. Watch whether companies hold or raise guidance while the report API chart package stays current.
Selected-security right-rail charts use weekly bars aggregated from discovery daily_ohlc through 2026-06-18. The page stores chart provenance and API routes, not static horizontal setup levels.
Basket
This basket is inherited from the parent theme and then updated for the June 21 filed security lanes. Ranking stays focused on source-backed procedure economics first, then cash-conversion proof and chart timing. BFLY and CLPT are now core because the lanes support direct procedure or workflow roles; they rank behind the established platforms because both are still loss-making and need repeated revenue, margin, and operating-cash-flow evidence. DXCM, PODD, and TNDM remain market-data-only watch names because no filed security lanes were found; GMED remains a source-backed tail watch outside the core rank.
Robotic surgery installed-base platform with the clearest recurring-revenue link to procedure growth.
Market cap$159.4B
Next earningsJul 28, 2026 est.
Latest qtr revenue$2.771B
Role in stack
Hospitals buy, lease, and service da Vinci and Ion systems. Procedure growth pulls instruments, accessories, service, and lease revenue through the installed base; the gate is utilization, da Vinci 5 adoption, service margin, hospital budgets, and tariff cost.
Revenue mix
Q1 2026 revenue was led by instruments and accessories at $1.6864B, systems at $650.7M, and service at $433.7M. Recurring revenue was $2.3703B, or 86% of total revenue.
Proof burden
Procedure growth, da Vinci 5 adoption, recurring mix, service margin, tariff cost, and free cash flow need to move together without hospital-budget pressure slowing placements.
Structural-heart implant platform where TAVR and TMTT procedure adoption already shows up in sales and guidance.
Market cap$46.0B
Next earningsJul 23, 2026 est.
Latest qtr revenue$1.649B
Role in stack
Cardiac centers and structural-heart teams use SAPIEN TAVR, TMTT repair or replacement devices, and surgical valves. Procedure penetration becomes implant revenue when referral, coverage, durability, physician training, and hospital access hold.
Revenue mix
Q1 2026 sales were $1.6486B: TAVR $1.1973B, TMTT $175.1M, and Surgical $276.2M. TAVR remains the core franchise, while TMTT is the highest-growth second engine.
Proof burden
TAVR and TMTT growth must keep converting into raised guidance, gross margin, cash flow, and procedure adoption without durability, referral, or reimbursement problems.
Broad cardiovascular and MedSurg procedure platform with strong exposure and heavy execution tests.
Market cap$80.2B
Next earningsJul 22, 2026 est.
Latest qtr revenue$5.203B
Role in stack
Hospitals and specialists use BSX electrophysiology, WATCHMAN, vascular, urology, endoscopy, pain, and neuromodulation products. Procedure volume becomes sales if PFA, WATCHMAN, vascular, and MedSurg adoption offset integration and reimbursement friction.
Revenue mix
Q1 2026 net sales were $5.203B, with Cardiovascular at $3.503B and MedSurg at $1.701B. Cardiovascular remains the main node exposure and MedSurg is the diversification leg.
Proof burden
PFA, WATCHMAN, vascular, and MedSurg growth need to offset Penumbra integration, reimbursement, debt, and FCF tests while Cardiovascular keeps organic growth above plan.
Hospital and ASC procedure platform tied to implants, Mako robotics, surgical equipment, and neurovascular tools.
Market cap$109.3B
Next earningsJul 30, 2026 est.
Latest qtr revenue$6.020B
Role in stack
Hospitals, ASCs, and surgeons use SYK implants, Mako robotics, surgical instruments, endoscopy, medical equipment, neurotechnology, and vascular tools. The conversion gate is procedure volume, hospital capex, implant share, robotics pull-through, and recovery after the Q1 disruption.
Revenue mix
Q1 2026 net sales were $6.020B: MedSurg and Neurotechnology $3.207B and Orthopaedics $2.813B. FY2026 guidance still requires a catch-up from only 2.4% Q1 organic growth.
Proof burden
Management needs to show the Q1 disruption is behind it, organic growth catches up to the 2026 guide, and implant, Mako, neurotechnology, and equipment sales reach margin and cash.
Diversified procedure and chronic-care device platform with broad exposure and post-MiniMed comparability work.
Market cap$97.8B
Next earningsNot confirmed
Latest qtr revenue$9.807B
Role in stack
Hospitals, physicians, and chronic-care channels use MDT cardiovascular, neuroscience, surgical, monitoring, diabetes, and robotics products. The node converts through Cardiovascular growth, Hugo and surgical adoption, post-MiniMed comparability, margin, tariffs, and free cash flow.
Revenue mix
Q4 FY2026 revenue was $9.807B: Cardiovascular $3.797B, Neuroscience $2.751B, Medical Surgical $2.388B, and Diabetes $837M. Cardiovascular is the clearest current growth engine.
Proof burden
FY2027 guidance, post-MiniMed comparability, Cardiovascular growth, Hugo and surgical execution, tariff cost, and free cash flow need to prove the diversified platform is improving.
Sleep and breathing-health device and resupply platform with strong margin evidence but less direct procedure exposure.
Market cap$30.0B
Next earningsJul 30, 2026 est.
Latest qtr revenue$1.431B
Role in stack
Patients, physicians, home-care providers, and durable-medical-equipment channels use ResMed PAP devices, masks, resupply, adherence data, and residential-care software. Economics depend on diagnosis, adherence, resupply, reimbursement, channel inventory, and GLP-1 impact on OSA demand.
Revenue mix
Q3 FY2026 revenue was $1.431B. Sleep and Breathing Health was $1.2605B, about 88% of revenue; Residential Care Software was $170.9M, about 12%.
Proof burden
Sleep-device demand, masks, resupply, adherence software, gross margin, and cash conversion need to hold while the market watches GLP-1 effects and reimbursement or channel inventory pressure.
Diversified health-care manufacturer where medical devices and CGM carry the node exposure.
Market cap$146.9B
Next earningsJul 16, 2026 est.
Latest qtr revenue$11.164B
Role in stack
Hospitals, cardiologists, diabetics, and outpatient channels use Abbott devices including CGM, rhythm management, electrophysiology, heart failure, structural heart, and diagnostics-adjacent products. The gate is device growth, Libre sensor days, cardiovascular share, Exact integration, debt, and litigation.
Revenue mix
Q1 2026 net sales were $11.164B. Medical Devices supplied $5.539B and grew 8.1% ex-FX; Nutrition declined, Diagnostics had legacy pressure plus Exact contribution, and Established Pharmaceuticals was a useful but less central segment.
Proof burden
Medical Devices and CGM growth need to offset diagnostics pressure, Exact integration, added debt, dilution, litigation, and broader portfolio complexity.
Hospital imaging, contrast, patient-care, and software platform that needs better margin and backlog conversion.
Market cap$28.9B
Next earningsJul 29, 2026 est.
Latest qtr revenue$5.131B
Role in stack
Hospitals and imaging centers buy imaging, AVS, PCS, PDx, service, and workflow software. Aging and procedure volume matter when scans, contrast, service, and software convert backlog into revenue without tariff, China, PCS, or supplier pressure erasing margin.
Revenue mix
Q1 2026 revenue was $5.131B: Imaging $2.299B, AVS $1.341B, PCS $704M, and PDx $770M. Imaging and PDx are the cleaner node exposures; PCS and China are active drags.
Proof burden
Imaging and PDx backlog conversion must show up in guidance, gross margin, and cash while PCS weakness, China, tariffs, and supplier pressure stop getting worse.
Orthopedic implant and robotics route with direct exposure but the weakest current organic-growth proof.
Market cap$15.9B
Next earningsAug 6, 2026 est.
Latest qtr revenue$2.087B
Role in stack
Orthopedic surgeons and hospitals use ZBH knees, hips, sports medicine, extremities, trauma, ROSA robotics, and surgical tools. Procedure volume becomes economics only if commercial execution, implant share, robotics pull-through, integration, and free cash flow improve.
Revenue mix
Q1 2026 sales were $2.087B. Americas contributed $1.3245B, EMEA $489.9M, and Asia Pacific $272.3M; knees and hips remain the largest annual product categories.
Proof burden
Knee, hip, ROSA, trauma, and sports medicine demand need to translate into better organic growth, commercial execution, margin, and free cash flow.
Handheld semiconductor ultrasound, software, and AI workflow platform with a direct point-of-care role and a high cash-conversion burden.
Market cap$2.3B
Next earningsNot confirmed
Latest qtr revenue$26.5M
Role in stack
Clinicians, hospitals, public-health buyers, and enterprise channels use handheld Butterfly iQ ultrasound probes, cloud software, AI-enabled workflow, education, and embedded technology. Procedure and diagnostic demand becomes economics only if placements bring recurring software, enterprise, service, or embedded revenue rather than one-time hardware sales.
Revenue mix
Q1 2026 revenue was $26.5M: product revenue was $14.7M and software and other services revenue was $11.9M. Gross margin reached 68.9%, helped by higher-margin embedded licensing, which needs repeat evidence.
Proof burden
Q2 revenue needs to land within or above the $27M-$31M guide, FY2026 guidance needs to hold, gross margin needs to stay above FY2025's 46.9%, and operating cash flow needs to improve before dilution risk returns.
CNS navigation, neurocritical-care, and therapy-delivery platform with real partner adoption but still-negative cash economics.
Market cap$0.5B
Next earningsNot confirmed
Latest qtr revenue$12.1M
Role in stack
Neurosurgery centers and biopharma partners use ClearPoint navigation, IRRA flow, SmartFlow delivery, field support, and software to deliver therapy into the brain and spine. The conversion gate is installed-base utilization, repeat procedure revenue, partner funding, regulatory progress, and disclosed per-procedure economics.
Revenue mix
Q1 2026 revenue was $12.1M: about $5.9M from neurosurgery navigation and therapy, $4.8M from biologics and drug delivery, and $1.4M from capital equipment and software. Activated installed base exceeded 175 centers, with more than 60 biopharma partners.
Proof burden
Revenue must stay on pace for the $52M-$56M 2026 guide, IRRA integration needs to reduce 2H cash burn, partner programs need to keep ClearPoint embedded, and ATM or secured-debt usage cannot dilute the growth case.
Market caps use read-only discovery instruments.market_cap; existing large-cap values retain the 2026-06-13 query and BFLY/CLPT use 2026-06-21 read-only checks. Next-earnings dates are Nasdaq/Zacks estimates checked on 2026-06-13 for the legacy basket; BFLY and CLPT are labeled Not confirmed because the filed lanes did not include confirmed next report dates. Latest-quarter revenue uses the latest reported quarterly total revenue, not annualized revenue.
What Confirms Or Weakens
AreaWhat confirmsWhat weakens or invalidatesWatch next
01Node thesisProcedure demand converts
What confirms
Procedure volume, device utilization, implants, service, consumables, resupply, point-of-care ultrasound, CNS delivery cases, and imaging demand show up in revenue growth and held or raised guidance.
What weakens or invalidates
Procedure growth slows, hospital budgets delay orders, reimbursement pressure limits adoption, or company guidance is cut.
Watch next
Q2 and Q3 procedure growth
Hospital capex commentary
Procedure guide updates
02Economics mechanismRevenue reaches cash
What confirms
Recurring and service mix, implant volume, cardiovascular growth, imaging backlog conversion, software or embedded mix, gross margin, operating margin, FCF, and EPS move with sales.
What weakens or invalidates
Tariffs, freight, supplier disruption, integration costs, working capital, pricing pressure, litigation, cash burn, or equity issuance absorb revenue growth before cash flow.
Watch next
Margin bridge
FCF conversion
Backlog-to-revenue
BFLY/CLPT burn
03Customer and adoptionHospitals keep using products
What confirms
ISRG procedures and recurring revenue, EW TAVR and TMTT growth, BSX cardiovascular growth, SYK ortho and Mako recovery, MDT diversified growth, BFLY software mix, and CLPT installed-base use remain above plan.
What weakens or invalidates
ISRG valuation and da Vinci 5 cost drag, EW TAVR durability or TMTT scaling issues, BSX PFA or WATCHMAN pressure, SYK disruption delays, MDT FY2027 disappointment, BFLY margin reversal, or CLPT partner-program delay.
Watch next
Company releases
Product-cycle data
Procedure commentary
BFLY/CLPT guides
04Funding and policyBudget and coverage gate
What confirms
Hospital capex, payer coverage, Medicare and commercial reimbursement, and customer financing support adoption without pushing vendors into excessive discounts or lease cash absorption.
05Operating and supply constraintCosts stay contained
What confirms
Manufacturing scale-up, service costs, supplier availability, logistics, quality systems, recall cadence, and integration work let revenue growth reach gross margin and operating margin.
What weakens or invalidates
Tariffs, recalls, field actions, PDx supply issues, PCS weakness, China exposure, acquisition integration, sales-force disruption, or litigation costs lower conversion quality.
Watch next
Gross margin
Product quality
Integration costs
China and supply commentary
06Stale conditionRefresh trigger
What confirms
Knowledge lanes, official releases, and discovery rows remain current, and no new earnings release, FDA event, reimbursement update, guidance change, or partner-program update supersedes the cited evidence.
What weakens or invalidates
Local discovery rows stop refreshing, BFLY or CLPT publish guidance or financing news that supersedes the June 21 lanes, or the report API cannot resolve selected-security charts.
DXCM, PODD, and TNDM have local OHLC coverage through 2026-06-12 but no filed security lanes found in the knowledge index, so they remain market-data-only watch names. GMED has source-backed local coverage but is outside the parent core basket.
Earnings Date And Revenue Sources
Next-earnings checks used Nasdaq API endpoints on 2026-06-13 for the legacy basket. Nasdaq states the dates are algorithmic estimates from historical reporting dates and Zacks Investment Research, so the cards label them est.. Estimated dates: ISRG Jul 28, 2026; EW Jul 23, 2026; BSX Jul 22, 2026; SYK Jul 30, 2026; RMD Jul 30, 2026; ABT Jul 16, 2026; GEHC Jul 29, 2026; ZBH Aug 6, 2026. Nasdaq returned no upcoming date for MDT, and the BFLY/CLPT lanes did not include confirmed next report dates, so those cards use Not confirmed.
Latest-quarter revenue sources and periods: ISRG Q1 2026 8-K and 10-Q, $2.7708B; EW Q1 2026 10-Q and earnings release, $1.6486B; BSX Q1 2026 release, $5.203B; SYK Q1 2026 release, $6.020B; MDT June 3, 2026 FY2026 Q4 and full-year release, Q4 FY2026 revenue $9.807B; RMD Q3 FY2026 release and 10-Q, $1.431B; ABT Q1 2026 release and 10-Q, $11.164B; GEHC Q1 2026 release, 10-Q, and presentation, $5.131B; ZBH Q1 2026 release and 10-Q, $2.087B; BFLY Q1 2026 release and 10-Q, $26.5M; CLPT Q1 2026 release and 10-Q, $12.1M.
Read-only DuckDB checks on 2026-06-21 used instruments.market_cap for BFLY/CLPT card market caps and daily_ohlc for the updated 11-name basket. All core tickers had local daily OHLC rows through 2026-06-18: ABT, BFLY, BSX, CLPT, EW, GEHC, ISRG, MDT, RMD, SYK, and ZBH.
The node no longer stores static price thresholds in HTML or node JSON. Weekly OHLC uses first open, maximum high, minimum low, final close, and summed volume by calendar week, with 20-week EMA, 100-week EMA, and weekly volume assumptions provided by the selected-security report API.
The selected-security right rail uses the report API route pattern /api/securities/{ticker}/chart?frequency=weekly&window=3y&as_of=latest. The expected chart package is weekly OHLC from daily_ohlc, a three-year visible horizon, 20-week EMA, 100-week EMA when enough history exists, and volume subgraph, ordered by Basket rank.
Representative API check on 2026-06-13 for /api/securities/ISRG/chart?frequency=weekly&window=3y&as_of=latest could not connect because the local report API was not running on 127.0.0.1:8765. The June 21 update did not rerun live HTTP rendering.
Read-only discovery status checks for BFLY and CLPT on 2026-06-21 showed daily OHLC through 2026-06-18, short volume through 2026-06-18, and short interest through 2026-05-29. Both tickers had local filing metadata and no local 13F holdings rows.